What is Kinomica?
Founded in 2016, Kinomica operates at the intersection of advanced data science and molecular biology. The company specializes in the analysis of cell signaling, a critical area for understanding disease progression and therapeutic response. By providing deep insights into the kinome—the complete set of protein kinases in an organism—Kinomica enables more precise diagnostic tools and personalized medicine strategies. Its platform is designed to translate complex biological data into actionable intelligence, serving as a vital resource for pharmaceutical partners and clinical researchers aiming to optimize drug discovery and patient outcomes.
How much funding has Kinomica raised?
Kinomica has raised a total of $5.2M across 1 funding round:
Unspecified
$5.2M
Unspecified (2020): $5.2M with participation from Alderley Park, BioCity Group Limited, BGF Ventures, Longwall Ventures, and Puffin Point
Key Investors in Kinomica
BGF Ventures
BGF is the most active equity investor in the UK and Ireland, providing long-term, minority investment and value creation support to growing companies.
Longwall Ventures
Longwall Ventures invests in early stage deeptech businesses that leverage the UK's expertise in science R&D, focusing on addressing global challenges through innovative solutions.
Alderley Park
A prominent life science campus and investment hub that supports the growth of innovative biotech and health-tech companies through infrastructure and strategic capital.
What's next for Kinomica?
With the recent capital secured, Kinomica is expected to focus on scaling its diagnostic platform and expanding its footprint within the global life sciences market. The company's roadmap likely includes the enhancement of its proprietary proteomic-data pipelines and the pursuit of strategic partnerships to integrate its technology into broader clinical workflows. As the firm moves forward, the emphasis will remain on maintaining its competitive edge in deeptech innovation, ensuring that its diagnostic solutions remain at the forefront of the rapidly evolving precision medicine sector. The backing from experienced venture firms provides the necessary runway to navigate the complexities of commercializing high-impact biotech solutions.
See full Kinomica company page
